IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens

Equities research analysts at Stephens assumed coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $51.00 price target on the stock. Stephens’ price target points to a potential upside of 89.59% from the stock’s current price.

IDYA has been the subject of several other research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Stifel Nicolaus upped their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. Wedbush restated an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. decreased their price target on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Trading Up 1.0 %

Shares of NASDAQ IDYA opened at $26.90 on Monday. The stock has a market capitalization of $2.32 billion, a PE ratio of -11.43 and a beta of 0.86. IDEAYA Biosciences has a 12-month low of $26.41 and a 12-month high of $47.74. The stock’s fifty day simple moving average is $31.42 and its two-hundred day simple moving average is $36.30.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period in the previous year, the business posted ($0.46) earnings per share. On average, equities analysts predict that IDEAYA Biosciences will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its holdings in shares of IDEAYA Biosciences by 38.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after acquiring an additional 927 shares during the last quarter. Quest Partners LLC purchased a new stake in IDEAYA Biosciences in the second quarter valued at $41,000. Price T Rowe Associates Inc. MD grew its position in IDEAYA Biosciences by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock worth $177,825,000 after purchasing an additional 486,222 shares during the period. Scientech Research LLC raised its stake in shares of IDEAYA Biosciences by 362.3% during the 2nd quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after buying an additional 21,714 shares during the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new position in shares of IDEAYA Biosciences in the 1st quarter valued at about $1,431,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.